Multiple drug-resistant HBV mutation may contribute to poor response of adefovir + entecavir in entecavir-resistant patients.
PMID: 33571155
2021
Journal of infection in developing countries
Abstract: RESULTS: ETV-resistant mutants were continuously detected in 10 of the 12 patients, and multidrug-resistant (MDR) mutants, including a novel strain (rtL180M+A181V+T184A+S202G+M204V), were detected in two patients.
Detection of Hepatitis B Virus M204V Mutation Quantitatively via Real-time PCR.
PMID: 34007795
2021
Journal of clinical and translational hepatology
Table: T184A
Entecavir-resistant hepatitis B virus decreases surface antigenicity: A full genome and functional characterization.
Abstract: Three HBV isolates (8.3%) were identified with drug resistance mutations to lamivudine, entericavir, telbivudine and tenofovir, which are amino acid substitutions in the HBV polymerase gene at positions L180M, T184A, M204V.
Hepatitis B virus mutation pattern rtL180M+A181C+M204V may contribute to entecavir resistance in clinical practice.
Method: Recombinant vectors that harboured a patient-derived rtL180M+A181C+M204V, rtL180M+A181C+M204V+S202G, rtL180M+A181C+M204V+M250V mutant and wild-type RT genes, as well as another patient-derived rtL180M+S202G+M204V, rtL180M+T184
Patterns of hepatitis B virus S gene escape mutants and reverse transcriptase mutations among genotype D isolates in Jordan.
Abstract: RT mutations included: V173L, S202I, L180M, M204V and T184A.
Result: The first patient was a male with history of treatment with lamivudine who had mutations at established drug resistance positions: L180M, T184A, M204V which confer resistance to lamivudine, entecavir and telbivudine.
Table: T184A
Viral quasispecies of hepatitis B virus in patients with YMDD mutation and lamivudine resistance may not predict the efficacy of lamivudine/adefovir rescue therapy.
PMID: 30906435
2019
Experimental and therapeutic medicine
Result: Common and frequent mutations identified in the cohort of the present study included rtL80V/I, rtV84M, rtL91I, rtN118H/D/T, rtT128A, rtL180M, rtT184L/S/A, rtV191I, rtS202G, rtV207I/M, rtS213T
[Determination of reverse transcriptase inhibitor nucleoside analogue resistance profile in pretreatment phase of patients with viral hepatitis B].
Abstract: Primary drug resistance mutations such as rtI169T, rtA181T/V, rtT184A/C/F/G/I/L/M/S, rtA194T, rtS202C/G/I, rtM204I/V/S, rtN236T, rt M250I/L/V and rtV173L were not detected in any of the patient samples.
Potential resistant mutations within HBV reverse transcriptase sequences in nucleos(t)ide analogues-experienced patients with hepatitis B virus infection.
Introduction: These two categories are known as classical mutations, which include: (i) M204I/V mutation, which associates with LAM or LDT resistance; (ii) N236T or A181T/V mutations, which associate with ADV resistance; (iii) M204V + L180M and either T184A/G/I/L/S or S202G or M250V to develop resistance to ETV.
Discussion: reported that an combined mutation pattern of L80M, L180M, M204V/I, A200V, F221Y, S223A, T184A/L,
HBV mutation literature information.
PMID: 
2022
Frontiers in microbiology
Browser Board
Co-occurred Entities
Filtrator
ViMRT